May Daher

Engineered receptors for soluble cellular communication and disease sensing

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

Engineering precision nanoparticles for drug delivery

Trial Watch: Monoclonal antibodies in cancer therapy

Cancer immunoediting and resistance to T cell-based immunotherapy

Key role of the REC lobe during CRISPR–Cas9 activation by ‘sensing’, ‘regulating’, and ‘locking’ the catalytic HNH domain

Inflammation and tumor progression: signaling pathways and targeted intervention

Programmable synthetic receptors: the next-generation of cell and gene therapies

The immune contexture in human tumours: impact on clinical outcome

Harnessing innate immunity in cancer therapy

Mechanisms of resistance to CAR T cell therapy

Cell membrane-coated nanosized active targeted drug delivery systems homing to tumor cells: A review

Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses

Natural Killer Cell Therapy: A New Treatment Paradigm for Solid Tumors

RNA Structural Dynamics As Captured by Molecular Simulations: A Comprehensive Overview

Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering

Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy

Tuning RNA folding and function through rational design of junction topology

Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering

Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer

Case Series of Dermatologic Events Associated With the Insulin-Like Growth Factor Receptor 1 Inhibitor Cixutumumab